Investing.com - US stock futures rose on Tuesday after President Donald Trump stopped short of imposing universal import tariffs following his inauguration, while investors eyed the potential for fiscal stimulus and tax reductions during his administration.
Here's a look at some key stock movers in premarket US trading:
US-listed shares in Chinese companies jumped, in a sign of investor relief that China had at least initially avoided harsh levies that have been proposed by Trump. Alibaba (NYSE:BABA), JD.com (NASDAQ:JD), PDD (NASDAQ:PDD), and Baidu (NASDAQ:BIDU) all advanced prior to the opening bell on Wall Street.
Apple (NASDAQ:AAPL) shares slumped after analysts at Jefferies slashed their rating of the iPhone manufacturer to "underperform" from "hold", and independent research found that sales in China of the tech giant's flagship device plunged 18.2% during the December quarter.
Scotch tape-maker 3M Co. (NYSE:MMM) reported fourth-quarter results that exceeded analyst expectations, while its 2025 earnings outlook was largely in line with consensus estimates. Shares rose in premarket trading.
General Motors (NYSE:GM) shares increased after analysts at Deutsche Bank (ETR:DBKGn) improved their rating of the carmaker to "buy" from "hold", adding that they expect the group to post in the high-end of its guidance range in the fourth quarter.
Urban Outfitters (NASDAQ:URBN) shares gained after analysts at Morgan Stanley (NYSE:MS) upgraded their rating of the clothing retailer to "overweight" from "equal-weight", citing room for the stock's value to grow despite a recent rally.
Charles Schwab (NYSE:SCHW) shares spiked after the financial services company posted adjusted fourth-quarter earnings per share that beat average analyst estimates.
DR Horton (NYSE:DHI) shares climbed after the home construction company backed its full-year revenue and deliveries forecasts.
Walgreens (NASDAQ:WBA) shares slumped after the Department of Justice sued the pharmacy chain, alleging that it dispensed opioids and other controlled substances at locations across the US and ignored concerns around the legality of the prescriptions.